Northwest Biotherapeutics: Highlights of the 2014 10-K (NWBO, Buy, $7.81)Introduction Northwest Biotherapeutics just issued their 10-K for 2014 and I would urge everyone to read it. The purpose of this… Northwest Biotherapeutics Stock Surges 94% on Perfect Storm Created by Short Squeeze and New Buying Interest (NWBOD, $10.75)Investment Summary A.P. Pharma: Refiling of NDA for APF530 Could Lead to Stock Price StrengthCatalyst Thoughts on Northwest Biotherapeutics’ Reverse Stock SplitNorthwest Biotherapeutics (NWBO.OB) announced a 1 for 16 reverse stock split. This is a first step in a planned public… Discovery Laboratories: The Street Is Getting on Board With MeMy Recent History on Discovery Laboratories On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at… An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)
I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report… Manish Singh Resigns as CEO of ImmunoCellular Therapeutics: Implications for Northwest Biotherapeutics and ImmunoCellularImmunoCellular (IMUC.OB) has issued a press release stating that Manish Singh has resigned as CEO. He will be succeeded in… Johnson & Johnson: A Core Holding for the Long Haul
I have just written a report on JNJ in which I reiterated my Buy recommendation. I don’t see a vibrant… Cadence Pharmaceuticals Ofirmev Has Gained Traction Producing Upside Surprise in 2Q, 2012I reiterate my Buy recommendation on Cadence. The Ofirmev launch has now gained traction as just reported 2Q, 2012 revenues… Price Drop Following Side Effect Issue with Hepatitis C Pipeline Drug Creates Buying OpportunityBristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094,… Cadence Pharmaceuticals’ Ofirmev Launch is Gaining Traction (CADX, $4.02)Investment Background Stock Weakness Following Equity Offering Provides A Buying Opportunity in A.P. Pharma (APPA, $0.58)Investment Thesis The equity offering by A.P. Pharma of 102 million shares at $0.52 per share has put pressure on the… Amylin Acquisition is a Mild Positive for Bristol-Myers SquibbI prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy… A.P. Pharma: Ondansetron's Link to QT Interval Prolongation is a Huge Positive for APF530The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to… Cadence (CADX): Ofirmev Sales Could Surprise on the Upside in Second Quarter and Generic Concerns Appear to be OverblownCadence (CADX) has just released estimates from the independent market research firm Wolters, Kluwer on the number of vials that… Trius' (TSRX) Tedizolid Has Blockbuster Potential for MRSA InfectionsTrius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that… Discovery Laboratories (DSCO): An Update and Buy Re-iterationI have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing… Initiating Coverage of A.P. Pharma with a Buy (APPA, $0.42)I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015… Highlighting A New Report on Dendritic Cell Cancer VaccinesNorthwest Biotherapeutics’ (NWBO) DCVax-L and ImmunoCellular Therapeutics’ ICT-107 are dendritic cell cancer vaccines that are in phase II trials for… Dendreon Turns Reins Over to New CEOKey Points Dendreon has made a sweeping change in management by bringing in John Johnson, who was serving as a board… Gilead's Offer for Pharmasset Follows Closely on the Heels of Roche's Bid for Anadys: Could Achillion and Inhibitex Be Next?Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11… Transcept to Resubmit Intermezzo NDA; Hopes for a Class I ReviewResubmission of Intermezzo NDA Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA… Bristol-Myers Squibb's Dapagliflozin Voted Down By Advisory Committee; What's NextOverview of Advisory Committee Meeting The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 6-9 against approval of dapagliflozin for the… |